International Study Finds New Drugs Combination to Cut Deaths from Diabetes

The largest-ever study of treatments for diabetes has shown that a combination of two blood pressure-lowering drugs reduces the risk of death, heart attack and kidney disease in diabetes sufferers. The "Action in diabetes and vascular disease" (ADVANCE) project involves 20 countries from around the world, 12 of them from the EU. The results were presented at the European Society of Cardiology Congress in Vienna, Austria, on 3 September.

A total of 11,140 patients took part in trials, which lasted over four years. Half of the participants received a fixed combination of two blood pressure-lowering drugs (perindopril and indapamide) in a single tablet, daily. The other half received a matching inactive placebo.

"These results represent an important step forward in health care for millions of people with diabetes worldwide," said Professor Stephen MacMahon from the George Institute for International Health in Australia. "This treatment reduced the likelihood of dying from the complications of diabetes by almost one-fifth, with virtually no side-effects."

Type 2 diabetes is the most common form of diabetes, mostly affecting adults. Sufferers are known to be at a high risk of developing major health problems earlier in life than those without diabetes. In particular, sufferers are more likely to experience a heart attack, stroke, blindness, kidney failure and leg ulcers that can lead to amputation.

The study participants were already receiving most of the standard treatments for diabetes, including other drugs to lower blood pressure. But the precise combination used in this study resulted in a 14% reduction in the risk of death, and an 18% reduction in the risk of death from cardiovascular disease. "In absolute terms, one death would be avoided for every 79 patients treated with the fixed combination of perindopril and indapamide for five years," said Study Director Dr Anushka Patel, also from the George Institute.

Currently around 250 million people worldwide have diabetes, and this number is growing rapidly. The majority of these people will either die or become disabled by the complications inherent in their condition.

For further information, please visit:
http://www.advance-trial.com/static/html/prehome/prehome.asp

Copyright ©European Communities, 2007
Neither the Office for Official Publications of the European Communities, nor any person acting on its behalf, is responsible for the use, which might be made of the attached information. The attached information is drawn from the Community R&D Information Service (CORDIS). The CORDIS services are carried on the CORDIS Host in Luxembourg - http://cordis.europa.eu. Access to CORDIS is currently available free-of-charge.

Most Popular Now

Fasenra (benralizumab) receives US FDA approval fo…

AstraZeneca and its global biologics research and development arm, MedImmune, announced that the US Food and Drug Administration (FDA) has approved Fasenra (benralizumab)...

A great place to do great things: Developing game-…

Science has spoken: Abbott (NYSE: ABT) is, again, among the best science-based companies to work for in the world. For the 14th year, the journal Science today recognized...

Alzheimer's disease might be a 'whole body' proble…

Alzheimer's disease, the leading cause of dementia, has long been assumed to originate in the brain. But research from the University of British Columbia and Chinese scie...

Cancer cells destroyed with dinosaur extinction me…

Cancer cells can be targeted and destroyed with the metal from the asteroid that caused the extinction of the dinosaurs, according to new research by an international col...

Novartis confirms leadership in multiple sclerosis…

Novartis today announced it will present 54 scientific abstracts from across its multiple sclerosis (MS) research portfolio at the 7th Joint European and Americas Committ...

Amgen and Novartis announce expanded collaboration…

Amgen (NASDAQ:AMGN) and Novartis announced an expanded collaboration with the Banner Alzheimer's Institute (BAI) to initiate a new trial - the Alzheimer's Prevention Init...

Transplanted hematopoietic stem cells reverse dama…

Researchers at University of California San Diego School of Medicine report that a single infusion of wildtype hematopoietic stem and progenitor cells (HSPCs) into a mous...

Scientists find where HIV 'hides' to evade detecti…

In a decades-long game of hide and seek, scientists from Sydney's Westmead Institute for Medical Research have confirmed for the very first time the specific immune memor...

'Precision Medicine' may not always be so precise

Precision Medicine in oncology, where genetic testing is used to determine the best drugs to treat cancer patients, is not always so precise when applied to some of the w...

Novartis announces the planned acquisition of Adva…

Novartis announced today, that it has entered a memorandum of understanding with Advanced Accelerator Applications (AAA) under which Novartis intends to commence a tender...

New tissue-engineered blood vessel replacements on…

Researchers at the University of Minnesota have created a new lab-grown blood vessel replacement that is composed completely of biological materials, but surprisingly doe...

China's out of control 'silent killer' affects one…

More than one-third of adults in China have high blood pressure - often dubbed the "silent killer" for its lack of symptoms - but only about one in 20 have the condition ...

Pharmaceutical Companies

[ A | B | C | D | E | F | G | H | I | J | K | L | M | N | O | P | Q | R | S | T | U | V | W | X | Z ]